UCB opts for alliance as it picks Astellas as new Cimzia partner in Japan
This article was originally published in Scrip
Executive Summary
UCB has wasted no time securing another partner for Cimzia (certolizumab pegol) in Japan following Otsuka Pharmaceutical's recent decision to end its local alliance for the pegylated antibody with the Belgian firm.